Carisma Therapeutics Profit Margin

Carisma Therapeutics (CARM) currently reports a profit margin of 220.15% as of September 2025. That compares with -314.78% in the prior-year period — up 169.9% year over year. That is above the Healthcare sector average of 21.34%. Use the charts on this page to explore Carisma Therapeutics's profit margin history and peer comparisons.

Carisma Therapeutics's profit margin increased from -314.78% to 220.15% — a 169.9% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Carisma Therapeutics's profit margin of 220.15% is higher than the Healthcare sector average of 21.34%. That is roughly 931.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Carisma Therapeutics's current 220.15% should be judged against Healthcare norms (sector average: 21.34%) and against CARM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 220.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Carisma Therapeutics, and consider following CARM for alerts when major investors trade the stock.